Aspergillosis Market
授權報價
| Single User License | $4,500 USD |
| Multiple User License | $5,500 USD |
| Custom Research License | $8,000 USD |
完整報告名稱與涵蓋範圍
Aspergillosis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Chronic Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis (ABPA), Invasive Aspergillosis), By Drug Type (Isavuconazole, Voriconazole, Amphotericin-B, Itraconazole, Corticosteroids, Posaconazole, Others), By Route of Administration (Oral, Intravenous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region & Competition, 2021-2031F
報告摘要
Market Overview
The Global Aspergillosis Market is projected to expand from USD 4.73 Billion in 2025 to USD 5.99 Billion by 2031, exhibiting a Compound Annual Growth Rate (CAGR) of 4.01%. This market encompasses diagnostic technologies and antifungal pharmacotherapies used for identifying and treating infections caused by Aspergillus mold species. A primary growth driver is the increasing global population of immunocompromised individuals, such as organ transplant recipients and cancer chemotherapy patients, who are highly susceptible to severe fungal diseases. With an estimated 1.8 million annual global cases of chronic pulmonary aspergillosis in 2024, as reported by the Global Action Fund for Fungal Infections, a consistent demand for effective treatments and accurate diagnostics is assured.However, market expansion faces a significant hurdle due to the escalating issue of antimicrobial resistance. The growing prevalence of Aspergillus strains unresponsive to standard azole-based treatments complicates clinical management and necessitates the use of alternative drugs, which often carry higher toxicity or costs. This resistance profile creates regulatory and developmental obstacles for pharmaceutical companies, limiting the widespread adoption of first-line therapies and hindering the market's overall growth.
Market Driver
A key market driver is the expanding pipeline of novel antifungal therapeutics and strategic collaborations, driven by the critical need to combat multi-drug resistant fungal strains. Pharmaceutical developers are increasingly securing substantial funding to advance late-stage clinical trials for new drug classes, such as orotomides, which offer alternative mechanisms of action against resistant molds. For instance, F2G secured $100 million in September 2024 to support the regulatory approval and commercialization of its novel antifungal agent, olorofim, highlighting the industry's dedication to overcoming limitations of current azole-based therapies and ensuring a steady flow of innovative treatments.Concurrently, the rising incidence of invasive aspergillosis among high-risk patient groups is significantly broadening the market's commercial scope. The prevalence of these severe infections has surged due to modern medical interventions that suppress immune function, necessitating aggressive and costly antifungal management. Updated global estimates from the International Society for Infectious Diseases in September 2024 indicated over 2.1 million annual cases of invasive aspergillosis. This increasing disease burden directly boosts revenue generation for established pharmacotherapies, as evidenced by Basilea Pharmaceutica's antifungal Cresemba reaching $489 million in total global in-market sales for the twelve-month period ending March 2024, reflecting the urgent demand for effective treatment options.
Market Challenge
The escalating problem of antimicrobial resistance presents a formidable challenge that impedes the growth of the Global Aspergillosis Market. The increasing prevalence of Aspergillus strains unresponsive to standard azole-based treatments compels clinicians to forsake first-line therapies in favor of second-line alternatives, which are frequently more costly and linked to greater toxicity. This shift complicates patient management and elevates the economic burden on healthcare systems, thereby stifling the smooth integration of standard antifungal pharmacotherapies. Furthermore, the proliferation of resistance introduces market volatility, as pharmaceutical companies encounter heightened developmental risks and regulatory scrutiny when introducing new antifungal agents.Validating the severity of this impediment, recent statistics reveal a concerning prevalence of resistant cases. According to the Centers for Disease Control and Prevention (CDC), an estimated 19% of Aspergillus fumigatus infections in medical centers within certain regions in 2024 were resistant to azole antifungals. This substantial proportion of resistant infections directly hinders market expansion by rendering widely available treatments ineffective for a significant patient segment, consequently fragmenting the market and slowing the overall adoption of established therapeutic interventions.
Market Trends
The increasing adoption of rapid non-invasive diagnostic technologies is transforming clinical protocols by reducing the need for invasive procedures such as bronchoscopy and lung biopsies. Clinicians are progressively integrating urine-based antigen testing to accelerate time-to-diagnosis for invasive aspergillosis, particularly in patients with hematologic malignancies where swift diagnosis is crucial for survival. This technological advancement addresses the limitations of traditional culture methods and serum biomarkers, which often produce delayed or ambiguous results, by offering a patient-friendly alternative that facilitates earlier therapeutic intervention. Pearl Diagnostics' newly approved MycoMEIA Aspergillus Assay, cleared by the FDA in August 2025, demonstrated approximately 90% sensitivity in clinical validation, providing a precise non-invasive tool to enhance disease detection rates.Simultaneously, there is a notable shift toward prophylactic antifungal regimens aimed at preventing infections in high-risk transplant recipients before onset. Pharmaceutical companies are actively expanding the labels of long-acting echinocandins and other novel agents to include prevention in allogeneic blood and marrow transplant patients, moving beyond reactive treatment strategies. This proactive approach is driven by the substantial economic and clinical value of averting severe fungal episodes in immunocompromised hosts, thereby reducing hospital stays and systemic toxicity. CorMedix projected that peak annual sales for the antifungal rezafungin in its expanded prophylaxis indication could exceed $200 million following its acquisition of Melinta Therapeutics in August 2025, underscoring the market's strong focus on preventive care.
Key Market Players
* Pfizer Inc.
* Merck & Co., Inc.
* Astellas Pharma Inc.
* Gilead Sciences, Inc.
* Bayer AG
* Novartis AG
* Bristol-Myers Squibb Company
* Basilea Pharmaceutica Ltd.
* F2G Ltd.
* Mayne Pharma Group Ltd.
Report Scope
In this report, the Global Aspergillosis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
# Aspergillosis Market, By Type
* Chronic Pulmonary Aspergillosis
* Allergic Bronchopulmonary Aspergillosis (ABPA)
* Invasive Aspergillosis
# Aspergillosis Market, By Drug Type
* Isavuconazole
* Voriconazole
* Amphotericin-B
* Itraconazole
* Corticosteroids
* Posaconazole
* Others
# Aspergillosis Market, By Route of Administration
* Oral
* Intravenous
# Aspergillosis Market, By Distribution Channel
* Hospital Pharmacies
* Retail Pharmacies
* Online Pharmacies
# Aspergillosis Market, By Region
* North America
United States
Canada
Mexico
* Europe
France
United Kingdom
Italy
Germany
Spain
* Asia Pacific
China
India
Japan
Australia
South Korea
* South America
Brazil
Argentina
Colombia
* Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Aspergillosis Market.
Available Customizations:
Global Aspergillosis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
* Detailed analysis and profiling of additional market players (up to five).
目錄 Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Aspergillosis Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type (Chronic Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis (ABPA), Invasive Aspergillosis)
5.2.2. By Drug Type (Isavuconazole, Voriconazole, Amphotericin-B, Itraconazole, Corticosteroids, Posaconazole, Others)
5.2.3. By Route of Administration (Oral, Intravenous)
5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
5.2.5. By Region
5.2.6. By Company (2025)
5.3. Market Map
6. North America Aspergillosis Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Drug Type
6.2.3. By Route of Administration
6.2.4. By Distribution Channel
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Aspergillosis Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Drug Type
6.3.1.2.3. By Route of Administration
6.3.1.2.4. By Distribution Channel
6.3.2. Canada Aspergillosis Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Drug Type
6.3.2.2.3. By Route of Administration
6.3.2.2.4. By Distribution Channel
6.3.3. Mexico Aspergillosis Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Drug Type
6.3.3.2.3. By Route of Administration
6.3.3.2.4. By Distribution Channel
7. Europe Aspergillosis Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Drug Type
7.2.3. By Route of Administration
7.2.4. By Distribution Channel
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Aspergillosis Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Drug Type
7.3.1.2.3. By Route of Administration
7.3.1.2.4. By Distribution Channel
7.3.2. France Aspergillosis Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Drug Type
7.3.2.2.3. By Route of Administration
7.3.2.2.4. By Distribution Channel
7.3.3. United Kingdom Aspergillosis Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Drug Type
7.3.3.2.3. By Route of Administration
7.3.3.2.4. By Distribution Channel
7.3.4. Italy Aspergillosis Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By Drug Type
7.3.4.2.3. By Route of Administration
7.3.4.2.4. By Distribution Channel
7.3.5. Spain Aspergillosis Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By Drug Type
7.3.5.2.3. By Route of Administration
7.3.5.2.4. By Distribution Channel
8. Asia Pacific Aspergillosis Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Drug Type
8.2.3. By Route of Administration
8.2.4. By Distribution Channel
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Aspergillosis Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Drug Type
8.3.1.2.3. By Route of Administration
8.3.1.2.4. By Distribution Channel
8.3.2. India Aspergillosis Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Drug Type
8.3.2.2.3. By Route of Administration
8.3.2.2.4. By Distribution Channel
8.3.3. Japan Aspergillosis Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Drug Type
8.3.3.2.3. By Route of Administration
8.3.3.2.4. By Distribution Channel
8.3.4. South Korea Aspergillosis Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Drug Type
8.3.4.2.3. By Route of Administration
8.3.4.2.4. By Distribution Channel
8.3.5. Australia Aspergillosis Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Drug Type
8.3.5.2.3. By Route of Administration
8.3.5.2.4. By Distribution Channel
9. Middle East & Africa Aspergillosis Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Drug Type
9.2.3. By Route of Administration
9.2.4. By Distribution Channel
9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Aspergillosis Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Drug Type
9.3.1.2.3. By Route of Administration
9.3.1.2.4. By Distribution Channel
9.3.2. UAE Aspergillosis Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Drug Type
9.3.2.2.3. By Route of Administration
9.3.2.2.4. By Distribution Channel
9.3.3. South Africa Aspergillosis Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Drug Type
9.3.3.2.3. By Route of Administration
9.3.3.2.4. By Distribution Channel
10. South America Aspergillosis Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By Drug Type
10.2.3. By Route of Administration
10.2.4. By Distribution Channel
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Aspergillosis Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Drug Type
10.3.1.2.3. By Route of Administration
10.3.1.2.4. By Distribution Channel
10.3.2. Colombia Aspergillosis Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Drug Type
10.3.2.2.3. By Route of Administration
10.3.2.2.4. By Distribution Channel
10.3.3. Argentina Aspergillosis Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Drug Type
10.3.3.2.3. By Route of Administration
10.3.3.2.4. By Distribution Channel
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Aspergillosis Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Pfizer Inc.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Merck & Co., Inc.
15.3. Astellas Pharma Inc.
15.4. Gilead Sciences, Inc.
15.5. Bayer AG
15.6. Novartis AG
15.7. Bristol-Myers Squibb Company
15.8. Basilea Pharmaceutica Ltd.
15.9. F2G Ltd.
15.10. Mayne Pharma Group Ltd.
16. Strategic Recommendations
17. About Us & Disclaimer
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 TechSci Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們